DLBCL specialist Dr. Jeong Kim from St. Vincent’s Hospital in South Korea shares findings at the ASCO 2024 conference in June from the ECHELON-3 study about how the treatment combination of brentuximab vedotin, lenalidomide, and rituximab helps diffuse large B-cell lymphoma (DLBCL) patients whose disease has become resistant to or returned after prior therapy. Read a summary of the key findings below.
Brentuximab vedotin (Adcentris) is an antibody-drug conjugate that targets cancer cells directly, delivering a toxin to kill them. Lenalidomide (Revlimid) boosts the immune system’s ability to fight cancer and inhibits tumor growth. Rituximab (Rituxan) is an antibody that specifically binds to cancer cells, marking them for destruction by the immune system.
These medications are FDA-approved in different treatment settings for types of lymphomas. Their use as a treatment combination for DLBCL has not yet been proven. The goal of the ECHELON-3 study is to assess how effective this treatment combination is for relapsed/refractory DLBCL.
The study found the following after assessing the use of brentuximab vedotin, lenalidomide, and rituximab as a treatment combination for relapsed/refractory DLBCL:
In conclusion, the triplet combination of brentuximab vedotin, lenalidomide, and rituximab offers relapsed/refractory DLBCL patients an improved amount of time in a disease-free state following treatment compared to the doublet regimen of lenalidomide and rituximab. The triplet therapy may provide additional hope to patients who cannot receive other DLBCL treatments, such as CAR T-cell therapy or bispecific antibodies. Further follow-ups and studies will help confirm these findings.
We invite you to click the button below to subscribe to our newsletter and stay updated on the latest advancements in diffuse large B-cell lymphoma.
JOIN THE HEALTHTREE FOR DLBCL NEWSLETTER
DLBCL specialist Dr. Jeong Kim from St. Vincent’s Hospital in South Korea shares findings at the ASCO 2024 conference in June from the ECHELON-3 study about how the treatment combination of brentuximab vedotin, lenalidomide, and rituximab helps diffuse large B-cell lymphoma (DLBCL) patients whose disease has become resistant to or returned after prior therapy. Read a summary of the key findings below.
Brentuximab vedotin (Adcentris) is an antibody-drug conjugate that targets cancer cells directly, delivering a toxin to kill them. Lenalidomide (Revlimid) boosts the immune system’s ability to fight cancer and inhibits tumor growth. Rituximab (Rituxan) is an antibody that specifically binds to cancer cells, marking them for destruction by the immune system.
These medications are FDA-approved in different treatment settings for types of lymphomas. Their use as a treatment combination for DLBCL has not yet been proven. The goal of the ECHELON-3 study is to assess how effective this treatment combination is for relapsed/refractory DLBCL.
The study found the following after assessing the use of brentuximab vedotin, lenalidomide, and rituximab as a treatment combination for relapsed/refractory DLBCL:
In conclusion, the triplet combination of brentuximab vedotin, lenalidomide, and rituximab offers relapsed/refractory DLBCL patients an improved amount of time in a disease-free state following treatment compared to the doublet regimen of lenalidomide and rituximab. The triplet therapy may provide additional hope to patients who cannot receive other DLBCL treatments, such as CAR T-cell therapy or bispecific antibodies. Further follow-ups and studies will help confirm these findings.
We invite you to click the button below to subscribe to our newsletter and stay updated on the latest advancements in diffuse large B-cell lymphoma.
JOIN THE HEALTHTREE FOR DLBCL NEWSLETTER
about the author
Megan Heaps
Megan joined HealthTree in 2022. As a writer and the daughter of a blood cancer patient, she is dedicated to helping patients and their caregivers understand the various aspects of their disease. This understanding enables them to better advocate for themselves and improve their treatment outcomes. In her spare time, she enjoys spending time with her family, sewing, and cooking.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.